These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 10945314

  • 1. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking.
    Sellers EM, Kaplan HL, Tyndale RF.
    Clin Pharmacol Ther; 2000 Jul; 68(1):35-43. PubMed ID: 10945314
    [Abstract] [Full Text] [Related]

  • 2. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo.
    Sellers EM, Ramamoorthy Y, Zeman MV, Djordjevic MV, Tyndale RF.
    Nicotine Tob Res; 2003 Dec; 5(6):891-9. PubMed ID: 14668073
    [Abstract] [Full Text] [Related]

  • 3. Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior.
    Tyndale RF, Sellers EM.
    Ther Drug Monit; 2002 Feb; 24(1):163-71. PubMed ID: 11805739
    [Abstract] [Full Text] [Related]

  • 4. Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity.
    Kharasch ED, Hankins DC, Taraday JK.
    Drug Metab Dispos; 2000 Jan; 28(1):28-33. PubMed ID: 10611136
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of nicotine metabolism by methoxysalen: Pharmacokinetic and pharmacological studies in mice.
    Damaj MI, Siu EC, Sellers EM, Tyndale RF, Martin BR.
    J Pharmacol Exp Ther; 2007 Jan; 320(1):250-7. PubMed ID: 17021260
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro.
    Zhang W, Kilicarslan T, Tyndale RF, Sellers EM.
    Drug Metab Dispos; 2001 Jun; 29(6):897-902. PubMed ID: 11353760
    [Abstract] [Full Text] [Related]

  • 7. Determinants of the rate of nicotine metabolism and effects on smoking behavior.
    Johnstone E, Benowitz N, Cargill A, Jacob R, Hinks L, Day I, Murphy M, Walton R.
    Clin Pharmacol Ther; 2006 Oct; 80(4):319-30. PubMed ID: 17015050
    [Abstract] [Full Text] [Related]

  • 8. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk.
    Tyndale RF, Sellers EM.
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 2):548-52. PubMed ID: 11259349
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: effects of methoxsalen, a CYP2A5/6 inhibitor.
    Alsharari SD, Siu EC, Tyndale RF, Damaj MI.
    Nicotine Tob Res; 2014 Jan; 16(1):18-25. PubMed ID: 23884323
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Decreasing smoking behaviour and risk through CYP2A6 inhibition.
    Sellers EM, Tyndale RF, Fernandes LC.
    Drug Discov Today; 2003 Jun 01; 8(11):487-93. PubMed ID: 12818518
    [Abstract] [Full Text] [Related]

  • 14. Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance.
    Hukkanen J, Jacob P, Benowitz NL.
    Clin Pharmacol Ther; 2006 Nov 01; 80(5):522-30. PubMed ID: 17112808
    [Abstract] [Full Text] [Related]

  • 15. Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism.
    Mwenifumbo JC, Lessov-Schlaggar CN, Zhou Q, Krasnow RE, Swan GE, Benowitz NL, Tyndale RF.
    Clin Pharmacol Ther; 2008 Jan 01; 83(1):115-21. PubMed ID: 17522595
    [Abstract] [Full Text] [Related]

  • 16. A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption.
    Tyndale RF, Pianezza ML, Sellers EM.
    Nicotine Tob Res; 1999 Jan 01; 1 Suppl 2():S63-7; discussion S69-70. PubMed ID: 11768189
    [Abstract] [Full Text] [Related]

  • 17. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine.
    Mwenifumbo JC, Tyndale RF.
    Pharmacogenomics; 2007 Oct 01; 8(10):1385-402. PubMed ID: 17979512
    [Abstract] [Full Text] [Related]

  • 18. Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6.
    Denton TT, Zhang X, Cashman JR.
    Biochem Pharmacol; 2004 Feb 15; 67(4):751-6. PubMed ID: 14757175
    [Abstract] [Full Text] [Related]

  • 19. Metabolism and disposition kinetics of nicotine.
    Hukkanen J, Jacob P, Benowitz NL.
    Pharmacol Rev; 2005 Mar 15; 57(1):79-115. PubMed ID: 15734728
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.